Approximately 400 cancer drivers have been discovered, but fewer than 10% are targeted by the newer precision therapies. Furthermore, that subset is almost entirely composed of protein kinases or enzymes. There’s a critical need to extend drug targeting to other classes of oncogenic drivers.
